Physician
Hematology
Dr. Nishan H. Fernando, MD
|
|
Give Review
Nishan H. Fernando works in the field of Hematology. He studied medicine at Duke University School of Medicine. Duke University School of Medicine is a top medical college. Duke University School of Medicine is ranked 8 in research and 29 in primary care medicine He received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Nishan H. Fernando, MD has written publications. He has 13 publications published with PubMed. The lastest publication is: 'A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer.' He is registered with Medicare and accepts Medicare payments.
Publications
- A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer.
- A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal Carcinoma.
- Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal Cancer: phase I trial results.
- Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallBladder carcinoma: a 23-year experience.
- Successful desensitization to oxaliplatin.
- Targeted therapy of colorectal Cancer: clinical experience with bevacizumab.
- Inhibition of vascular endothelial growth factor in the treatment of colorectal Cancer.
- Biliary tract injury during cholecystectomy: a retrospective descriptive review of clinical features, treatment and outcome.
- A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable Cancer of the pancreas and distal biliary tract.
- A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal Cancer.
- A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
- Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Schools
Duke University School Of Medicine
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
Duke University Hospital -
Duke University School of Medicine
Hospital
-
Emory Saint Joseph's Hospital of Atlanta -
Northside Hospital -
Gwinnett Hospital System -
North Fulton Regional Hospital -
St. Joseph's Hospital
Drug Facts
| NPI NUMBER | 1154309938 | |
| NPPES Provider LastName | FERNANDO | |
| NPPES Provider FirstName | NISHAN | |
| NPPES Provider ZIPCode | 300417623 | |
| NPPES Provider State | GA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1628.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 231.0 | |
| Percent Opioid Claims | 14.19 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1154309938 |
| Last Name Of The Provider | FERNANDO |
| First Name Of The Provider | NISHAN |
| View All |
Similar Doctors
|
|
Dr. Kelly A. May, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Colleen S. Austin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas E. Seay, MD |
|
|
Dr. Jorge P. Leguizamo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sreekanth C. Reddy, MD
This Doctor is OpenDoctor Recommended.
|